Agennix AG is a Germany-based biopharmaceutical company. The Company focuses on the development of therapies, which improve the lives of critically ill patients in areas of major unmet medical need. The Company is focused on pharmaceutical companies and biotechnology firms with presence in the area of critical care and/or cancer development and commercialization. The Company's investigational agents include oral talactoferrin; a topical gel formulation of talactoferrin for treating chronic wounds, and RGB-286638, a multi-targeted kinase inhibitor in Phase I testing for cancer. The Company's site of operation is in Princeton, New Jersey.
AGENNIX AG 
